Benzinga Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the development of a novel\n more…
Globe Newswire Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas\n\n Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas\n\nCINCINNATI, Ohio, June 14, 2023 (GLOBE NEWSWIRE) -- Blue Water ...\n more…